Background Venous thromboembolism (VTE) often complicates the clinical course of cancer.
The risk is further increased by chemotherapy, but the trade‐off between safety and efficacy …

Evidence has recently emerged on the influence of gender on the immune system. In this
systematic review and meta-analysis of phase III randomized clinical trials (RCTs), we explored …

Background Recent evidence suggested a potential correlation between overweight and the
efficacy of immune checkpoint inhibitors (ICIs) in cancer patients. Patients and methods We …

… 2 ; overweight, 25 kg/m 2 ≤ BMI ≤29.9 kg/m 2 ; obese, BMI ≥30 kg/m 2 . In order to
properly weighing the role of baseline concomitant medication, their association with ECOG-PS, …

In ambulatory patients with solid cancer, routine thromboprophylaxis to prevent venous
thromboembolism is not recommended. Several risk prediction scores to identify cancer patients …

Introduction The potential to accurately quantify epidermal growth factor receptor (EGFR)
mutations in plasma from non–small-cell lung cancer patients would enable more rapid and …

Genomics has greatly improved how patients with cancer are being treated; however,
clinical-grade genomic biomarkers for chemotherapies are currently lacking. Using whole-genome …

Background Patients with a history of autoimmune diseases (AIDs) have not usually been
included in clinical trials with immune checkpoint inhibitors. Materials and Methods …

The immune system seems to play a fundamental role in breast cancer responsiveness to
chemotherapy. We investigated two peripheral indicators of immunity/inflammation, ie …

Background Immune-related adverse events (irAEs) developed during immunotherapy with
anti-PD-1 agents, could be a predictive surrogate marker of clinical benefit in patients with …